DK1882700T3 - Biotinylerede MHC-komplekser og deres anvendelser - Google Patents

Biotinylerede MHC-komplekser og deres anvendelser

Info

Publication number
DK1882700T3
DK1882700T3 DK07101561.4T DK07101561T DK1882700T3 DK 1882700 T3 DK1882700 T3 DK 1882700T3 DK 07101561 T DK07101561 T DK 07101561T DK 1882700 T3 DK1882700 T3 DK 1882700T3
Authority
DK
Denmark
Prior art keywords
applications
mhc complexes
biotinylated mhc
biotinylated
multimerising
Prior art date
Application number
DK07101561.4T
Other languages
English (en)
Inventor
Nikolai Franz Gregor Schwabe
Catherine Elizabeth Napper
Original Assignee
Prolmmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolmmune Ltd filed Critical Prolmmune Ltd
Application granted granted Critical
Publication of DK1882700T3 publication Critical patent/DK1882700T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/32—Post-translational modifications [PTMs] in chemical analysis of biological material biotinylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK07101561.4T 2006-07-25 2007-02-01 Biotinylerede MHC-komplekser og deres anvendelser DK1882700T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0614735A GB2442048B (en) 2006-07-25 2006-07-25 Biotinylated MHC complexes and their uses

Publications (1)

Publication Number Publication Date
DK1882700T3 true DK1882700T3 (da) 2011-05-16

Family

ID=37006102

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07101561.4T DK1882700T3 (da) 2006-07-25 2007-02-01 Biotinylerede MHC-komplekser og deres anvendelser

Country Status (6)

Country Link
US (2) US20080038282A1 (da)
EP (1) EP1882700B1 (da)
AT (1) ATE496943T1 (da)
DE (1) DE602007012176D1 (da)
DK (1) DK1882700T3 (da)
GB (1) GB2442048B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3878922B2 (ja) * 2003-04-24 2007-02-07 独立行政法人科学技術振興機構 脂質セカンドメッセンジャー検出・定量用プローブとそれを用いた脂質セカンドメッセンジャーの検出および定量方法
JP5779599B2 (ja) 2010-02-17 2015-09-16 ワン ラムダ， インコーポレイテッド 天然ヒト白血球抗原に対する抗体を検出するための組成物および方法
CA2872003C (en) * 2011-04-29 2021-08-10 The Board Of Regents Of The University Of Oklahoma Selective anti-hla antibody removal device and methods of production and use thereof
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
CN108474791B (zh) 2015-10-22 2022-07-08 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
CN116693695A (zh) 2017-02-12 2023-09-05 百欧恩泰美国公司 基于hla的方法和组合物及其用途
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN112125959B (zh) * 2020-10-10 2022-07-29 中山大学肿瘤防治中心 一种抑制eb病毒的肽和编码该肽的dna及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US5252466A (en) * 1989-05-19 1993-10-12 Biotechnology Research And Development Corporation Fusion proteins having a site for in vivo post-translation modification and methods of making and purifying them
DE4237113B4 (de) * 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
CA2140591A1 (en) * 1994-01-20 1995-07-21 Josef Endl Antigen-specific, activated t lymphocytes, detection and use
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US20020151707A1 (en) * 1995-06-07 2002-10-17 Corixa Corp. Immune mediators and related methods
JP2000504934A (ja) * 1995-12-22 2000-04-25 バクスター バイオテク テクノロジー エス．アー．アール．エル． 結合ドメインを含むグロビン
JP2000516808A (ja) * 1996-08-05 2000-12-19 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｍｈｃ結合ペプチドオリゴマーおよび使用方法
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
DE19641876B4 (de) * 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
US6248564B1 (en) * 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US8609436B2 (en) * 2000-03-17 2013-12-17 Guy's & St Thomas' Hospital NHS Trust (“GST”) Method
CA2406378A1 (en) * 2000-04-12 2001-10-25 University Of Rochester Targeted vaccine delivery systems
US20020082411A1 (en) * 2001-01-23 2002-06-27 Darrick Carter Immune mediators and related methods
DE10117858A1 (de) * 2001-04-10 2002-10-24 Gsf Forschungszentrum Umwelt MHC-Tetramere
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
US6902921B2 (en) * 2001-10-30 2005-06-07 454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
GB0202018D0 (en) * 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
US20040132133A1 (en) * 2002-07-08 2004-07-08 Invitrogen Corporation Methods and compositions for the production, identification and purification of fusion proteins
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
GB2408507B (en) * 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
GB2424645B (en) * 2005-04-01 2007-06-06 Proimmune Ltd Method of producing a set of MHC molecules

Also Published As

Publication number Publication date
DE602007012176D1 (de) 2011-03-10
ATE496943T1 (de) 2011-02-15
EP1882700A1 (en) 2008-01-30
GB0614735D0 (en) 2006-09-06
EP1882700B1 (en) 2011-01-26
GB2442048B (en) 2009-09-30
GB2442048A (en) 2008-03-26
US20150031566A1 (en) 2015-01-29
US20080038282A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
ATE496943T1 (de) Biotinylierte mhc-komplexe und ihre verwendungen
CY2021011I1 (el) Μεθοδοι και συνθεσεις με βαση συζευγματα τοξινης της διφθεριτιδας-ιντερλευκινης-3
DK1866339T3 (da) GTR-bindende molekyler og anvendelser heraf
CY1118120T1 (el) Συνθεσεις βασιζομενες σε πεδιο ινωδονεκτινης τυπου iii, μεθοδοι και χρησεις αυτων
JOP20190083A1 (ar) بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CY1113188T1 (el) Τροποποιημενα fgf-21 πολυπεπτιδια και οι χρησεις τους
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
CY1115059T1 (el) Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα
CY1112912T1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK2064334T3 (da) Aldehydtags, anvendelser deraf i site-specifik proteinmodificering
EP2010566A4 (en) POLYPEPTIDES WITH IMPROVED INFLAMMATORY INHIBITORS AND REDUCED CYTOTOXIC PROPERTIES AND CORRESPONDING METHODS
NO20091064L (no) Antistoffer mot IL-17A
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
CY1115735T1 (el) Τα διαζοδικυκλα μορια μιμητες smac και οι χρησεις αυτων
DE602007009373D1 (de) Kombination aus einem anti-edb-fibronectin-domänen-antikörper/il2-fusionsprotein und einem weiteren kleinen molekül
DE602006021441D1 (de) Schlauch zur beförderung von kryogenen fluiden
DK3202779T3 (da) Hgh polypeptider med langtidsvirkning og anvendelser deraf
CY1113074T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
DE602006015793D1 (de) Proteolipidmembran und lipidmembranen-biosensor
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
CY2018021I2 (el) Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει
DK2328931T3 (da) Selektive anti-hepcidin-25-antistoffer og anvendelser deraf
CY1113770T1 (el) Κυκλικα αντι-μικροβιακα πεπτιδια
ATE537183T1 (de) Hiv-fusionshemmerpeptide mit verbesserten biologischen eigenschaften
BRPI0821622A2 (pt) Patinets e veículos autoproulsionado ou impulsionado pelo pé